The observed alterations in FGF-2, FGF-19, FGF-22, and FGF-23 concentrations—particularly their associations with hypertension, obesity, nephropathy, and joint degeneration—support their role not only in the pathogenesis but also in the clinical stratification of diabetic complications. The gene discussed is FGF23; the disease is obesity disorder.